TWST · Twist Bioscience Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $53.59M | $49.73M | $44.76M | $46.77M | $45.87M | $46.19M | $44.42M | $42.54M | $41.84M | $41.67M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $19.70M | $17.13M | $18.05M | $23.92M | $21.31M | $22.47M | $24.15M | $23.10M | $24.53M | $27.38M |
| SG&A | $76.08M | $69.74M | $63.37M | $63.67M | $56.18M | $56.79M | $55.62M | $52.84M | $46.06M | $53.97M |
| Total Operating Expenses | $156.58M | $136.60M | $126.18M | $134.35M | $123.36M | $170.39M | $124.19M | $118.47M | $124.52M | $121.82M |
| D&A | $6.10M | $6.19M | $5.80M | $6.40M | $6.38M | $7.00M | $7.00M | $8.17M | - | - |
| Operating Income | ($45.86M) | ($32.90M) | ($30.12M) | ($41.56M) | ($34.64M) | ($88.92M) | ($48.89M) | ($46.98M) | ($60.78M) | ($61.64M) |
| Interest Expense | - | - | - | $0 | $0 | $0 | $0 | $0 | $1.0K | $2.0K |
| Income Tax | $43.0K | $253.0K | $191.0K | $175.0K | $97.0K | $191.0K | $345.0K | $120.0K | $622.0K | $676.0K |
| Net Income | ($44.02M) | ($30.51M) | $20.39M | ($39.33M) | ($31.59M) | ($85.57M) | ($45.49M) | ($43.01M) | ($57.40M) | ($59.16M) |
| EPS - Basic | ($0.71) | ($0.50) | $0.34 | ($0.66) | ($0.53) | ($1.47) | ($0.79) | ($0.75) | ($1.01) | ($1.04) |
| EPS - Diluted | ($0.71) | ($0.50) | $0.33 | ($0.66) | ($0.53) | ($1.47) | ($0.79) | ($0.75) | ($1.01) | ($1.04) |
Balance Sheet
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $122.67M | $148.59M | $183.05M | $210.44M | $221.40M | $226.32M | $243.35M | $266.27M | $286.47M | $315.20M |
| Accounts Receivable | $64.15M | $50.06M | $57.02M | $49.95M | $39.31M | $34.90M | $35.99M | $35.35M | $44.06M | $48.19M |
| Inventory | $33.52M | $32.92M | $28.31M | $20.86M | $23.52M | $24.08M | $30.38M | $30.86M | $32.06M | $39.92M |
| Accounts Payable | $14.68M | $12.49M | $11.09M | $8.06M | $7.50M | $1.63M | $7.70M | $9.26M | $14.05M | $13.24M |
| Current Assets | $323.44M | $303.88M | $332.97M | $338.44M | $345.31M | $346.78M | $371.87M | $390.23M | $424.26M | $489.27M |
| Total Assets | $676.21M | $638.09M | $641.86M | $595.62M | $608.58M | $614.32M | $702.85M | $732.82M | $776.40M | $853.92M |
| Current Liabilities | $119.98M | $80.44M | $91.41M | $74.98M | $69.65M | $71.01M | $67.49M | $65.23M | $73.32M | $72.11M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $221.12M | $181.99M | $168.90M | $155.51M | $152.64M | $141.63M | $142.72M | $142.77M | $152.97M | $149.99M |
| Stockholders' Equity | $455.09M | $456.10M | $472.96M | $440.11M | $455.94M | $472.69M | $560.13M | $590.04M | $623.43M | $703.93M |
| Retained Earnings | ($1.39B) | ($1.35B) | ($1.32B) | ($1.31B) | ($1.27B) | ($1.24B) | ($1.12B) | ($1.08B) | ($1.03B) | ($929.40M) |
Cash Flow
| Line item | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($24.81M) | - | - | ($21.43M) | - | - | ($22.97M) | - | - |
| Investing Cash Flow | - | ($9.93M) | - | - | ($1.54M) | - | - | $4.17M | - | - |
| Financing Cash Flow | - | $298.0K | - | - | $17.94M | - | - | ($1.47M) | - | - |
| CapEx | - | $9.97M | - | - | $2.27M | - | - | $1.51M | - | - |
| Free Cash Flow | - | ($34.79M) | - | - | ($23.70M) | - | - | ($24.48M) | - | - |
Ratios
| Metric | Q2 '26 | Q1 '26 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 1.14 | - | - | 0.75 | - | - | 0.57 | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | 0.9% | - | - | - | - | - | - | - |
| Return on assets | -6.5% | -4.8% | 3.2% | -6.6% | -5.2% | -13.9% | -6.5% | -5.9% | -7.4% | -6.9% |
| Return on equity | -9.7% | -6.7% | 4.3% | -8.9% | -6.9% | -18.1% | -8.1% | -7.3% | -9.2% | -8.4% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.70 | 3.78 | 3.64 | 4.51 | 4.96 | 4.88 | 5.51 | 5.98 | 5.79 | 6.79 |
| Quick ratio | 2.42 | 3.37 | 3.33 | 4.24 | 4.62 | 4.54 | 5.06 | 5.51 | 5.35 | 6.23 |
| Cash ratio | 1.02 | 1.85 | 2.00 | 2.81 | 3.18 | 3.19 | 3.61 | 4.08 | 3.91 | 4.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -60781.0x | -30818.5x |
| Equity multiplier | 1.49 | 1.40 | 1.36 | 1.35 | 1.33 | 1.30 | 1.25 | 1.24 | 1.25 | 1.21 |
| Liabilities / Assets | 0.33 | 0.29 | 0.26 | 0.26 | 0.25 | 0.23 | 0.20 | 0.19 | 0.20 | 0.18 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 1.60 | 1.51 | 1.58 | 2.24 | 1.95 | 1.92 | 1.46 | 1.38 | 1.31 | 1.04 |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 228d | 242d | 231d | 163d | 187d | 190d | 250d | 265d | 280d | 350d |
| Days payable outstanding | 100d | 92d | 90d | 63d | 60d | 13d | 63d | 79d | 123d | 116d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | 85.3x | - | - | - | - | - | - | - |
| P / B | 6.4x | 4.2x | 3.6x | 5.3x | 6.0x | 5.6x | 3.5x | 3.6x | 1.9x | 1.2x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -10.4% | 5.0% | 66.1% | 15.0% | 26.3% | -46.3% | 20.7% | -5.3% | 0.6% | -1.4% |
| Net income growth (YoY) | -11.9% | 3.4% | - | 13.5% | 26.5% | -49.1% | 23.1% | -2.8% | 5.2% | 2.5% |
| EPS growth (YoY) | -7.6% | 5.7% | - | 16.5% | 29.3% | -45.5% | 24.0% | -1.4% | 6.5% | -33.3% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -46.8% | - | - | 3.2% | - | - | 62.9% | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 3.4% | 0.0% | 0.1% | -21.4% | -22.7% | -24.2% | -20.4% | -20.9% | -21.0% | -18.5% |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Twist Bioscience Corp against the 5 most active filers in the same SIC group.